Report Highlights
-
The total worldwide market for orphan drugs, including sales for nonorphan applications, exceeded $28 billion in 2003.
-
This market is expected to rise at an AAGR (average annual growth rate) of 9.1% to reach $43.6 billion in 2008.
-
As a percentage of overall global drug sales, orphans are expected to increase their share from 7.0% in 2003 to 7.5% in 2008, as growth of the orphan market outpaces that of the total market.
-
As of mid-2003, 221 orphan drugs had been developed for the treatment of rare diseases affecting about 11 million patients.
-
Some orphan products have sales in excess of $1 billion annually.
INTRODUCTION
An orphan drug is defined by the U.S. Food and Drug Administration as a product that treats a disease affecting 200,000 or fewer Americans. A disease that affects fewer than this number is considered a rare disease. It is one for which there is not a great deal of incentive to develop products because of the small market. However, there are an estimated 6,000 rare diseases that collectively affect 25 million Americans. Approximately 70% are caused by genetic defects that have life-threatening consequences.
The Orphan Drug Act was implemented in 1983 to provide incentives for companies to develop products to treat diseases that annually affect from less than a dozen to a few hundred thousand people in the U.S. Because of the small patient numbers, these products were not expected to generate sufficient revenues to pay for their development. However, some products that originally were approved as orphan drugs had sales in excess of $1 billion.
This BCC report provides an in-depth look at the life stories of drugs with orphan disease designation(s) that have sales in excess of $200 million. The report examines in detail orphan drugs that have become multimillion-dollar products, provides revenues for leading orphan products, presents current and future strategies of companies developing these products as well as the diseases addressed, describes current and possible future legislation affecting development and marketing of orphan drugs in the U.S. and internationally, and examines the historical and current relationship between the biotech industry and the Orphan Drug Act as well as the future relationship of pharmacogenomics to the Act.
SCOPE OF STUDY
The report contains:
- An overview of orphan drug criteria, the history of the Orphan Drug Act and its influence, and advantages inherent in orphan drug designation
- Detailed discussion of successful orphan products, recently introduced products with an equivalent potential, and selected products in development
- Sales projections through 2008 for many of the 26 products analyzed
- A discussion of applications to specific orphan diseases for which products exist, and sales leaders
- An outline of legislation and regulation, including public and private agencies involved in support and development
- Analysis of the orphan drug industry, outlining leading companies and their successful product strategies.
METHODOLOGY
The base year for this study is 2003. Market figures are based on revenues at the manufacturers' level and are projected at 2003 dollar value (i.e., inflation is not computed into the projection figures).
Data to prepare this study was derived from information obtained from product managers, marketing strategists, research executives, government agency spokespersons and directors of organizations focused on specific orphan diseases. In addition, information also was obtained from others at pharmaceutical and biotechnology companies that have products for orphan diseases on the market or in development.
INFORMATION SOURCES
The information and analysis presented in this report are based on an extensive survey of the pharmaceutical industry as well as a detailed examination of published literature and reports obtained from regulatory authorities, medical research institutions, pharmaceutical trade associations, and national and world health organizations. Key information from the literature was used as to obtain expert opinion on commercial potential and market sizes from industry professionals.
AUTHOR'S CREDENTIALS
Lynn Gray has been a research analyst since 1989 and with BCC since 1996. During that time, she has authored numerous reports in the biomedical field, 18 for BCC alone. BA, University of California, Riverside, 1973.
Related Reports
Recent Reports
Gastrointestinal Therapeutics and Diagnostics: Technologies and Global Markets
The global market for gastrointestinal (GI) therapeutics and diagnostics is expected to grow from $86.0 billion in 2023 and projected to reach $122.5 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2023 to 2028.
Global Markets and Technologies for Advanced Drug Delivery Systems
The global market for advanced drug delivery systems is expected to increase from $262.6 billion in 2023 to $359.1 billion by the end of 2028, with a compound annual growth rate (CAGR) of 6.5% during the forecast period of 2023-2028.
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets
The global market for prostate cancer care is expected to grow from $37.9 billion in 2023 to $56.4 billion by the end of 2028, at a compound annual growth rate (CAGR) of 8.3% from 2023 through 2028.
Global Markets for Vaccine Technologies
The global market for vaccine technologies is expected to grow from $45.0 billion in 2023 to $65.3 billion by the end of 2028, at a compound annual growth rate (CAGR) of 7.8% from 2023 to 2028.
Chagas Disease: American trypanosomiasis Market
The report provides detailed coverage of the Chagas Disease market. It analyzes the market trends and epidemiology of CD, and the regional markets of CD. It highlights the current market for CD and gives a detailed analysis of the competitive environment. The report depicts the complete scenario of Chagas Disease, types of parasites that cause human African trypanosomiasis (HAT) and its presence in various regions of the world.
Top Trending Reports
Cell and Gene Therapy Tools, and Reagents: Global Markets
The global market for cell and gene therapy tools and reagents is estimated to grow from $8.3 billion in 2022 to $13.7 billion in 2027, with a compound annual growth rate (CAGR) of 10.6% for the period of 2022-2027.
Flame Retardant Chemicals: Technologies and Global Markets
The global consumption of flame retardant chemicals is estimated to grow from 6.0 billion pounds in 2022 to 7.5 billion pounds in 2027, at a compound annual growth rate (CAGR) of 4.4% for the period of 2022-2027.
Biorefinery Products: Global Markets
The global market for biorefinery products is estimated to increase from $624.7 billion in 2022 to $920.0 billion by 2027, at a compound annual growth rate (CAGR) of 8.0% from 2022 through 2027.
Electric Vehicle Charging: Infrastructure and Global Markets
The global market for wired electric vehicle charging infrastructure is estimated to grow from $24.1 billion in 2022 to $81.1 billion in 2027, at a compound annual growth rate (CAGR) of 27.4% for the period of 2022-2027.
Digital Pathology: Technologies and Global Markets
The global digital pathology market is estimated to increase from $5.9 billion in 2022 to reach $10.7 billion by 2027, at a compound annual growth rate (CAGR) of 12.5% from 2022 through 2027.
Become A Member
BCC Research offers a comprehensive library of reports, granting members unlimited access to data, insights, and market intelligence for informed business decisions, while actively supporting members in their evolving journeys and prioritizing high-quality, relevant topics based on continuous engagement with the research community.
Find Out MoreCustom Consulting
BCC Research emphasizes the importance of organizations leveraging highly customized market insights aligned with specific strategic business objectives through direct engagement with primary sources and proprietary forecasting models for profitable decision-making in maximizing growth opportunities and minimizing risks.
Customize NowScorecard
The Venture Scorecard provides commercialization offices and decision makers with expert analysis, offering strategic insights crucial for aligning objectives with market realities at various stages of commercializing new products or evaluating investment opportunities, from opportunity assessment to growth planning.
Find Out MoreInnovation Spotlight
Our industry experts offer strategic guidance to maximize the market potential of commercialized products, patents, and IP by providing insights into market trends, competitive dynamics, and effective positioning, using the Innovation Spotlight service for enhanced exposure to thought leaders and the wider community.
Find Out More